Close menu




August 19th, 2020 | 08:20 CEST

dynaCERT, TUI, Varta - where is it worth investing now?

  • Investments
Photo credits: pixabay.com

The Corona Pandemic has changed society and the economy in recent months. Topics such as social distancing did not exist in this extreme way before and has, for example, turned the travel industry upside down. As a result of government rescue measures, airlines and travel companies had to be provided with liquidity so that the systemically important corporations did not slip into insolvency through no fault of their own and much larger and more uncontrollable losses were caused by a domino effect. But a lot has also happened in the technology sector and there are exciting developments that can be lucrative for investors.

time to read: 2 minutes | Author: Mario Hose
ISIN: CA26780A1084 , DE000TUAG000 , DE000A0TGJ55

Table of contents:


    Partnership in the fight against climate change

    The Canadian technology company dynaCERT has brought an innovation to the market that makes existing diesel engines more environmentally friendly. The technology uses hydrogen as a catalyst and can therefore reduce the emission of pollutants. In addition, fuel consumption is reduced and, in addition to environmental protection, an economic advantage is created.

    dynaCERT recently announced that the company's HydraGEN (TM) units will now also participate in the United Nations program called "United 4 Smart Sustainable Cities". This means that dynaCERT is now an official partner of the United Nations in the fight against climate change in cities around the globe. Some 200 cities around the world have already joined the program, including capitals in Europe, Asia, the Middle East, Africa and North and South America. This partnership offers the company enormous sales and profit potential. The analysts of GBC see a price potential for the share of EUR 2.20.

    Setback due to travel warnings

    The German TUI Group clearly felt the effects of the travel restrictions and is therefore eligible to participate in the so-called Corona Shield of the German government. The largest aid package of the Federal Republic of Germany enables payments to be made via the state-owned Kreditanstalt für Wiederaufbau (KfW). In the second quarter of 2020 TUI has already received a payment of EUR 1.8 billion. Due to the ongoing precautionary measures the travel industry is still severely restricted and TUI requires a further credit line of EUR 1.05 billion from KfW.

    Against the background that the number of Covid-19 infections is on the rise again in many holiday regions, the industry is still far from normal travel behaviour. The travel warning issued by the German Foreign Office for Spain was a severe setback for the industry, as destinations such as Mallorca are among the most popular holiday destinations.

    Competence and growth

    The shares of battery manufacturer Varta can benefit from the trends of cordless headphones and the electrification of mobility. The business with lithium-ion cells is booming and the company was recently able to adjust its expectations for the current fiscal year upwards. Sales are expected to increase by up to 129% year-on-year to EUR 810 to 830 million, exceeding the previous estimate of up to EUR 800 million.

    With a market share of over 50% in rechargeable batteries for headphones, Varta's competence is undisputed and this market is extremely interesting due to its annual growth of up to 40%. Varta has received EUR 300 million from the German government for research and development and the first industrial application of next generation lithium ion cells. The analyst von Berenberg has raised the target price of the share from EUR 120.00 to EUR 140.00 and left the rating at 'buy'.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read